Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

William Blair cut their Q2 2026 earnings per share estimates for shares of Oracle in a report issued on Tuesday, March 11th.

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

Citi analysts increased their price target on Docusign to $115 from $113 and reiterated a Buy rating. “Revenue was a bit ...

William Blair analyst Tim Mulrooney maintained a Hold rating on ABM Industries (ABM – Research Report) today. The company’s shares opened today ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...